Danaher Corporation says its bioprocessing businesses Pall Biotech and Cytiva have secured over $1 billion in COVID-19 related orders and expects further windfalls as vaccines and therapies reach approval. When the coronavirus pandemic emerged earlier this year, commentators noted the financial opportunity for bioprocess vendors in supporting industry’s efforts in developing and commercializing vaccines, therapeutics, and diagnostics. As the year progresses, these opportunities are materializing in quarterly statements, with Danaher Corporation the latest company showing a COVID-19 tailwind across its…

Sartorius has raised its guidance citing growing demand for bioprocessing tech and lab services and the positive impact of acquisitions. Group revenue for the nine months to the end of September was €1.68 billion, up 23.9% on the comparable period last year. Bioprocess Solutions generated €1.28 billion, up 27.7%, while laboratory products and services brought in €391 million, up 13%. Sartorius said a general increase demand and the positive impact of recent takeovers were the major drivers. The COVID-19 pandemic…